The Tumor Burden Index (TBI) measures the tumor burden in patients with cutaneous T cell lymphoma by taking into account the types, number and severity of skin lesions. This can be used to estimate the prognosis and to help identify patients who might benefit from more or less aggressive therapy. The index performed better than the TNM stage for discrimination of survival and significance of differences.
Definitions for cutaneous foci of T-cell lymphoma:
(1) patch: visible but not palpable; histology shows eczematous patchy and scattered lymphocytes in papillary dermis
(2) plaque: palpable; histology shows a bandlike infiltrate filling the papillary dermis
(3) tumor: nodular, either exophytic or subcutaneous; histology shows a nodular infiltrate of lymphocytes involving the papillary and reticular dermis with extension into the subcutaneous tissue
Parameter |
Finding |
Points |
patches |
<= 30% BSA |
0 |
|
> 30% BSA |
1 |
plaques |
absent |
0 |
|
present |
1 |
tumors |
absent |
0 |
|
present |
1 |
tumor burden index =
= (2 * (points for patches)) + (2 * (points for plaques)) + (1.3 * (points for tumors)) + 1
Interpretation:
• possible indices: 1, 2.3, 3, 4.3, 5 and 6.3
Tumor Burden Index |
10 Year Survival |
1 or 2.3 |
100% |
3 |
64% |
4.3, 5 or 6 |
27% |
Other prognostic factors identified:
(1) Males tend to have a better prognosis than women.
(2) Age of onset and age at diagnosis did not correlate with prognosis.
Specialty: Hematology Oncology, Dermatology
ICD-10: ,